tetradecanoylphorbol acetate has been researched along with temozolomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aquino, A; Leonetti, C; Tentori, L | 1 |
| Darga, TE; Dolan, ME; Kufe, DW; Weichselbaum, RR; Wu, MH; Yamini, B; Yu, X | 1 |
2 other study(ies) available for tetradecanoylphorbol acetate and temozolomide
| Article | Year |
|---|---|
Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: role of alpha-6 integrin phosphorylation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Adhesion; Cell Membrane; Dacarbazine; Dose-Response Relationship, Drug; Integrin alpha6; Integrins; Male; Mice; Mice, Inbred C57BL; Naphthalenes; Phosphorylation; Protein Kinase C; Temozolomide; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1995 |
Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Damage; Guanine; Humans; Luciferases; Microscopy, Fluorescence; NF-kappa B; Protein Binding; Subcellular Fractions; Temozolomide; Tetradecanoylphorbol Acetate; Time Factors; Transcription Factor RelA | 2007 |